	US 12,109,199 B2
	Topical mTOR inhibitors for cutaneous proliferative and vascular conditions
Cynthia Marie Carver Deklotz, Bethesda, MD (US); and Robert A. Silverman, Arlington, VA (US)
Assigned to Georgetown University, Washington, DC (US)
Appl. No. 16/967,457
Filed by Georgetown University, Washington, DC (US)
PCT Filed Feb. 6, 2019, PCT No. PCT/US2019/016758 § 371(c)(1), (2) Date Aug. 5, 2020, PCT Pub. No. WO2019/156999, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/626,779, filed on Feb. 6, 2018.
Prior Publication US 2021/0177810 A1, Jun. 17, 2021
Int. Cl. A61K 31/436 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/436 (2013.01) [A61K 9/0014 (2013.01)]

9 Claims

1. A method of treating a cutaneous proliferative condition, comprising topically administering to an affected area of a subject in need thereof a therapeutically effective amount of a mammalian target of rapamycin (mTOR) inhibitor, thereby treating the condition, wherein the cutaneous proliferative condition is a cutaneous histiocytosis, wherein the mTOR inhibitor is selected from the group consisting of sirolimus and everolimus and is provided as a topical formulation comprising 0.01% to 10% (w/w) of the mTOR inhibitor in a pharmaceutically acceptable carrier.